Nicholas Piramal India Ltd (NPIL) has tied up with the Centre for Biochemical Technology (CBT) for conducting basic research in genomics.
The company has identified genetic associations, genetic preponderance, genetic basis of ayurveda as the thrust areas and around 20 scientists are currently working for the project.
Company officials informed that the project, named as GenoMed, would conduct clinical research in different therapeutic segments like diabetic and cancer. The duration of this project is 10 years.
Sources said that around 10 scientists from CBT and 10 from NPIL are working and the investment plans and other modalities are being worked out. The research activities will be conducted at the NPIL-promoted Wellspring Hospital in Mumbai.
They added that the project hopes to develop around 20 basic molecules in different therapeutic segment and at least three would take for different clinical trails.
They said NPIL recently has tied up with Central Drug Research Institute (CDRI) for developing molecules in the cardiology and diabetes. They said the compound were in the final lap of clinical trails and will take one more year for regulatory submissions.
NPIL is also conducting research in phytomedicine through the Quest centre it acquired from Hoechst Marion Roussell. Two of the centre's innovations - Rejoint and Ostop - are likely to rake in a revenue of over Rs 10 crore during the first year of the launch.
